8-K: Cellectar Biosciences Q3 2025: EMA Path, Clinical Progress

Cellectar Biosciences reports Q3 2025 financial results, advances regulatory strategy for iopofosine I-131 in Europe, and progresses its radioconjugate pipeline.

Summary

• Cellectar Biosciences announced financial results for the third quarter ended September 30, 2025, and provided a corporate update.
• The company expects to submit a Conditional Marketing Approval (CMA) application in Europe for iopofosine I-131 in refractory (post-BTKi) Waldenstrom's Macroglobulinemia (WM) in 2026, following advice from the European Medicines Agency (EMA) Scientific Advice Working Party (SAWP).
• A potential approval and commercialization of iopofosine I-131 for WM in Europe is anticipated in 2027.
• Initiated a Phase 1b study of CLR 125 for triple-negative breast cancer (TNBC) after receiving Investigational New Drug (IND) clearance.
• Received Rare Pediatric Drug Designation (RPDD) for iopofosine I-131 in inoperable relapsed/refractory pediatric high-grade glioma (r/r pHGG).
• Plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of iopofosine I-131 for WM once the confirmatory Phase 3 trial is underway, which is subject to sufficient funding.
• The planned Phase 3 study for iopofosine I-131 in WM will be a comparator, randomized controlled study with approximately 100 patients per arm, with full patient enrollment projected within 18-24 months of the first patient admitted.
• Presented preclinical data for CLR 225, a novel actinium-based radio conjugate alpha-emitter, showing inhibition of tumor growth or reduction in tumor volume in pancreatic cancer models; IND-enabling studies have been completed.
• Raised approximately $12.7 million, which will be used to advance the TNBC study and complete the EMA Conditional Marketing Authorization application for iopofosine I-131 for WM.
• Cash and cash equivalents were $12.6 million as of September 30, 2025, a decrease from $23.3 million as of December 31, 2024.
• The company believes its cash balance as of September 30, 2025, is adequate to fund its budgeted operations into the third quarter of 2026.
• Following the close of the third quarter in October 2025, institutional investors exercised warrants for gross proceeds of approximately $5.8 million.
• Research and Development (R&D) expenses for Q3 2025 were $2.5 million, a decrease from $5.5 million for Q3 2024.
• General and Administrative (G&A) expenses for Q3 2025 were $2.3 million, a decrease from $7.8 million for Q3 2024.
• Net loss attributable to common stockholders for Q3 2025 was $4.4 million, or $1.41 per basic and diluted share, compared to a net loss of $14.7 million, or $11.18 per basic share, in Q3 2024.

Sentiment

Score: 8

Explanation: The filing indicates strong progress in clinical development and regulatory pathways for key assets, particularly iopofosine I-131 in Europe and the US, alongside promising early-stage pipeline advancements. Financials show a substantial reduction in net loss and operating expenses, and recent capital raises extend the cash runway. However, the company still operates at a loss, and the US NDA submission is contingent on sufficient funding for the confirmatory trial, indicating ongoing financial dependency.

Positives

• EMA confirmation of eligibility to submit for a Conditional Marketing Approval (CMA) for iopofosine I-131 in Waldenstrom's Macroglobulinemia (WM), bringing closer to potential approval and commercialization in Europe by 2027.
• FDA Breakthrough Therapy Designation for iopofosine I-131 continues to support a path toward a New Drug Application (NDA) for accelerated approval.
• Initiation of a Phase 1b study for CLR 125 in triple-negative breast cancer (TNBC), building on strong preclinical data.
• Received Rare Pediatric Drug Designation (RPDD) for iopofosine I-131 in inoperable relapsed/refractory pediatric high-grade glioma (r/r pHGG).
• Interim data from the CLOVER-2 study showed extended progression-free survival and overall survival for iopofosine I-131 in r/r pHGG, with a well-tolerated toxicity profile.
• Preclinical data from CLR 225 demonstrated inhibition of tumor growth or reduction in tumor volume in pancreatic cancer models, with potential survival benefit.
• Completion of Investigational New Drug (IND)-enabling studies for CLR 225, maintaining the option to move into a Phase 1 study.
• Successfully raised approximately $12.7 million, with an additional $5.8 million from warrant exercises in October 2025, extending the cash runway.
• Significant reduction in net loss to $4.4 million in Q3 2025 from $14.7 million in Q3 2024.
• Research and Development (R&D) expenses decreased by 54.5% to $2.5 million in Q3 2025 compared to Q3 2024.
• General and Administrative (G&A) expenses decreased by 70.5% to $2.3 million in Q3 2025 compared to Q3 2024.
• Cash balance is adequate to fund budgeted operations into Q3 2026.

Negatives

• Cash and cash equivalents decreased to $12.6 million as of September 30, 2025, from $23.3 million as of December 31, 2024.
• Submission of the New Drug Application (NDA) for accelerated approval of iopofosine I-131 for Waldenstrom's Macroglobulinemia (WM) is explicitly subject to sufficient funding for the confirmatory trial.
• The company continues to operate at a net loss, despite significant reductions.

Risks

• Uncertainties related to the ability to identify suitable collaborators, partners, licensees, or purchasers for product candidates.
• Uncertainties related to the ability to enter into binding agreements with regard to any collaborations or partnerships.
• Uncertainties related to the ability to raise additional capital to support operations.
• Uncertainties related to the ability to fund operations if unsuccessful in securing collaborations or additional capital.
• Drug discovery and development inherently involve a high degree of risk.
• The New Drug Application (NDA) submission for iopofosine I-131 for Waldenstrom's Macroglobulinemia (WM) is contingent on sufficient funding for the confirmatory trial.

Future Outlook

The company expects to submit a Conditional Marketing Approval application in Europe for iopofosine I-131 in refractory Waldenstrom's Macroglobulinemia in 2026, with potential approval and commercialization in 2027. Plans are also in place to submit a New Drug Application to the U.S. FDA for accelerated approval of iopofosine I-131 for WM, contingent on sufficient funding for the confirmatory Phase 3 trial. The Phase 3 study is projected to achieve full patient enrollment within 18-24 months of the first patient. The company is also advancing its radioconjugate pipeline, including a Phase 1b trial for CLR 125 in triple-negative breast cancer and progressing CLR 225 into a potential Phase 1 study. The current cash balance is expected to fund operations into the third quarter of 2026.

Management Comments

• "Our productive engagement with the European Medicines Agency (EMA) highlighted by confirmation of eligibility to submit for a conditional marketing authorization marks a significant step forward in our global regulatory strategy, bringing us closer to potential approval and commercialization of iopofosine I-131 for WM in 2027." James Caruso, President and CEO.
• "In parallel, additional data from the CLOVER WaM study and the receipt of breakthrough designation from the FDA continues to support a path toward a New Drug Application for accelerated approval." James Caruso, President and CEO.
• "We believe this regulatory pathway, combined with the compelling clinical results we've seen to date, reinforces the value of iopofosine and positions it as a highly attractive asset for collaboration or strategic partnership." James Caruso, President and CEO.
• "Looking ahead, we are excited to further advance our promising radioconjugate pipeline of augerand alpha-emitting drug candidates and have initiated a Phase 1b trial for CLR 125 in triple-negative breast cancer, which builds on strong preclinical data showing reduction or inhibition of solid tumor growth." James Caruso, President and CEO.
• "We are also progressing our early-stage asset, CLR 225, which has shown robust anti-tumor activity in pancreatic cancer models, and has recently completed IND-enabling studies." James Caruso, President and CEO.
• "Each of these achievements brings us closer to our goal of transforming the outlook for patients facing aggressive and life-threatening cancers." James Caruso, President and CEO.

Industry Context

Cellectar Biosciences operates in the highly competitive and innovative biopharmaceutical sector, specifically focusing on radioconjugates for cancer treatment. The progress with iopofosine I-131 in Waldenstrom's Macroglobulinemia, including EMA conditional marketing approval eligibility and FDA Breakthrough Therapy designation, positions it as a potential leader in targeted radiotherapeutics for rare hematologic cancers. The expansion into solid tumors like triple-negative breast cancer and pancreatic cancer with CLR 125 and CLR 225, respectively, aligns with broader industry trends towards precision oncology and diversified pipelines, particularly in areas with high unmet medical need. The focus on Augerand alpha-emitting radioconjugates represents an advanced approach in targeted radiation therapy, aiming for improved efficacy and safety profiles compared to traditional treatments.

Comparison to Industry Standards

• The company's progress with iopofosine I-131 for Waldenstrom's Macroglobulinemia (WM) is notable, as WM is a rare disease with limited treatment options, especially for refractory patients. The EMA's confirmation of eligibility for Conditional Marketing Approval and FDA's Breakthrough Therapy Designation indicate a strong regulatory path, comparable to other innovative therapies for rare diseases that receive expedited review.
• The initiation of a Phase 1b study for CLR 125 in triple-negative breast cancer (TNBC) addresses a significant unmet need, as TNBC is an aggressive form of breast cancer with fewer targeted treatment options compared to other subtypes. This aligns with industry efforts to develop novel therapies for difficult-to-treat solid tumors.
• The preclinical data for CLR 225 in pancreatic cancer models is promising, as pancreatic ductal adenocarcinoma (PDAC) is one of the most challenging cancers to treat, often with poor prognoses. Developing alpha-emitter radioconjugates for such indications is at the forefront of oncology research, similar to efforts by companies like Actinium Pharmaceuticals (Actinium-225 programs) or Novartis (Pluvicto for prostate cancer, a beta-emitter).
• The company's cash runway into Q3 2026, supported by recent capital raises, is a common metric for early to late-stage biopharmaceutical companies, indicating sufficient liquidity for near-term operational and clinical milestones.

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical and regulatory progress, reduced net loss, and extended cash runway, potentially increasing future value. However, dilution from recent capital raises and warrant exercises.
• Patients (Waldenstrom's Macroglobulinemia): Potential for a new, targeted treatment option (iopofosine I-131) in 2027 in Europe and potentially earlier in the US via accelerated approval.
• Patients (Pediatric High-Grade Glioma): Potential for a new treatment option (iopofosine I-131) with positive interim data and Rare Pediatric Drug Designation.
• Patients (Triple-Negative Breast Cancer, Pancreatic Cancer): Hope for future treatment options as CLR 125 and CLR 225 progress through clinical and preclinical stages.
• Employees: Continued employment and potential growth opportunities as the pipeline advances.
• Creditors/Suppliers: Improved financial stability with extended cash runway, reducing immediate risk.

Next Steps

• Submit Conditional Marketing Approval application in Europe for iopofosine I-131 in WM in 2026.
• Achieve potential approval and commercialization of iopofosine I-131 for WM in Europe in 2027.
• Initiate confirmatory Phase 3 trial for iopofosine I-131 in WM (subject to sufficient funding).
• Submit New Drug Application (NDA) to the U.S. FDA for accelerated approval of iopofosine I-131 for WM once the confirmatory trial is underway.
• Continue Phase 1b/2a dose-finding study for CLR 125 in triple-negative breast cancer.
• Potentially move CLR 225 into a Phase 1 study.

Key Dates

Recommendation

The company has made significant clinical and regulatory strides, particularly with iopofosine I-131, which could lead to market approval in Europe by 2027 and potentially accelerated approval in the US. The financial performance shows improved cost control and a reduced net loss, and recent capital raises provide a runway into Q3 2026. These are strong positive indicators. However, the US NDA submission is explicitly contingent on "sufficient funding" for the confirmatory trial, highlighting ongoing capital dependency and potential future dilution. While the progress is encouraging, the stock remains speculative given the early to mid-stage nature of most pipeline assets and the need for further funding for pivotal trials. A "Hold" recommendation reflects the positive developments balanced against the inherent risks and future funding requirements typical of a clinical-stage biopharmaceutical company.

Keywords

Cellectar Biosciences, CLRB, biopharmaceutical, cancer treatment, radioconjugate, iopofosine I-131, Waldenstrom's Macroglobulinemia, WM, triple-negative breast cancer, TNBC, pediatric high-grade glioma, pHGG, CLR 125, CLR 225, EMA, FDA, Conditional Marketing Approval, NDA, Rare Pediatric Drug Designation, Breakthrough Therapy, Orphan Drug, Fast Track, oncology, clinical trials, Q3 2025, financial results